3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioma
3
Glioblastoma
3
Astrocytoma
2
Whooping Cough
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumococcal Infections
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Measles
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hepatitis B
1
HIV Infections
1
Gliosarcoma
1
Carcinoma
1
Advanced Cancer
1
Interventions
Temozolomide
93
Radiotherapy
66
Bevacizumab
35
Radiation
22
Carmustine
21
Erlotinib Hydrochloride
17
Chemotherapy, Adjuvant
17
Irinotecan
16
Magnetic Resonance Spectroscopy
13
Radiotherapy, Conformal
11
O(6)-benzylguanine
11
Surgical Procedures, Operative
10
Radiotherapy, Intensity-Modulated
10
sargramostim
9
Sirolimus
9
Imatinib Mesylate
9
Carboplatin
9
temsirolimus
8
motexafin gadolinium
7
Thalidomide
7
Gene Expression Profiling
7
aldesleukin
6
Sorafenib
6
Radiosurgery
6
Immunohistochemistry
6
Hydroxyurea
6
Gefitinib
6
Filgrastim
6
Everolimus
6
Etoposide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gliosarcoma
×
Tetanus Toxoid
×
Clear all
NCT00639639
2023-03-13
ATTAC
Duke University
Phase 1
Completed
42 enrolled